NCT00323570

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ NiaStase®) in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.

Conditions

• Acquired Bleeding Disorder
• Trauma

Interventions

Type	Name	Description
DRUG	activated recombinant human factor VII

Timeline

• Start date: 2006-05-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2006-05-09
• Last updated: 2012-06-27

Locations

42 sites across 1 country: United States